Global Head of Chemical and Pharmaceutical Profiling
Novartis Institutes for BioMedical Research
Sudhakar Garad received his Ph.D. from the Bombay College of Pharmacy, University of Mumbai, India in 1998 in Pharmaceutical Drug Delivery Technology with Dr, M.S Nagarsenker. Soon after completion of his Ph.D., he worked with Pfizer, India for less than a year in clinical research. Taking into consideration his excellent credentials during his Ph.D, he was selected as a post-doctoral fellow at the University of Connecticut to understand micro-environmental properties above dissolving surface of the polymers. After his post-doctoral fellowship, he worked with Vertex pharmaceutical for a period of three years as Senior Investigator in formulation development group. After Vertex, he joined Novartis as a Group Head. He worked with Novartis for 9 years and joined as a Director of formulation development at Cubist Pharmaceuticals/Merck for 2.5 years. Currently Sudhakar is working as a Global head of Chemical and Pharmaceutical profiling (Discovery Pharmaceutics) and Disease Area Head (New Indications) at Novartis. His primary role is collaborate with research colleagues and build the right biopharmaceutical properties into new chemical entities, if not enable them via solubility/dissolution enhancement technologies to expedite molecules into tox and clinical studies. He is also responsible for enabling research, clinical and commercial molecules via novel delivery technologies (Brain targeting, permeability enhancement, TI improvement etc). He has many publications, book chapters and patents. In last 20 years of his career he has taken more than 200 new chemical entities in clinical studies across dozen disease areas ( CVM, Oncology, ATI, MS, Respiratory, NS, GI, Antibacterial, Tropical diseases, HCV etc), via oral, parenteral, inhalation and transdermal route of administration. He serves as a technical R and D expert to research Disease Area for hematology, hepatology and kidney disease area.
Drug Delivery Leader, Biopharmaceutical Development, Cell and Gene Therapies, Innovation
Fellow Cell & Viral Vector Process Development
Magdalena holds a PhD from a University of Lausanne. She formerly worked at EMPA, St. Gallen – the Swiss Federal Laboratories for Materials Science and Technology.
During her career, she worked in multiple projects related to drug product formulation, tissue engineering, 3D in vitro systems and drug delivery systems.
After joining Novartis in 2015, she focused on cell and viral vector drug products pharmaceutical development. Magdalena contributed to multiple IND/IMPD filling including BLA filing for Kymriah, the first approved ATMPs in the US.
She is currently LVV Technical Development Lead for External Partners within Cell and Gene Technical Development at Novartis.
Magdalena is a member of APV Drug Delivery Focus Group, as an expert for ATMPs.
Bharathi Vellalore is a Pharmaceutical Scientist with >12 years of cross-functional research experience in discovery and development of cyclic peptides, small-proteins, antibody-based molecules and cell therapy products for diagnostic and therapeutic applications. Before joining Janssen Drug Product Development, he conducted postdoctoral research in the Saskatoon Translational Cancer Research Cluster and Janssen Biotherapeutics. Bharathi earned his MSc and PhD in Biochemistry from the University of Saskatchewan, Canada (2017) and BTech in Biotechnology from Anna University, India (2008).
Founder, Chairman, CEO
Susan Rosenbaum, J.D., is Founder, Chairman & CEO of Lauren Sciences; 10 years successful biotech visionary, entrepreneurial leader, strategic executive, motivated manager w/experience and expertise. Licensed breakthrough V-Smart® nanotechnology for BBB delivery from BGU, Israel; built Lauren Sciences LLC, multiple medical and scientific collaborations, 5-member MAB/SAB of KOLs, 12 foundation grant awards, innovative V-Smart® platform applications, transformative V-Smart® pipeline products in pre-clinical development for CNS; co-authored DD&D March 2018 cover feature, presented at 36 scientific conferences, w/posters at 7 scientific meetings, made Lauren Sciences a BIO 2018 winner and 1st Place Winner Global Healthcare Innovation at BIO 2019. Founder (present): Lauren Sciences LLC; Maya Sciences LLC; Founder (past): investment banking firm (Rosenbaum & Co.), corporate finance law firm (Rosenbaum, P.C.); Private and public company BODs; Nat’l/internat’l author/speaker.